Which GLP-1s Can Be Compounded? Semaglutide, Tirzepatide & the FDA Shortage-List Rules (2026)

In practice, the GLP-1 medications compounded for weight loss in 2026 are semaglutide and tirzepatide — and what is actually being compounded is the active pharmaceutical ingredient, not a brand-name product. You cannot "compound" Ozempic, Wegovy, Mounjaro, Zepbound, or Rybelsus: those are finished, FDA-approved drugs made by their manufacturers, and a compounding pharmacy works from raw semaglutide or tirzepatide drug substance, not from a branded pen or vial. The legal basis for compounding these two molecules also changed materially: large-scale compounding was permitted while each drug sat on the FDA drug-shortage list, but tirzepatide was resolved off the shortage list in late 2024 and semaglutide in early 2025, which closed the broad mass-compounding window. State-licensed 503A pharmacies can still compound for an individual patient when there is a documented clinical need — but routine "copy of the commercial drug" compounding is restricted. This guide explains which GLP-1s can and cannot be compounded, why the shortage list is the hinge, and which offerings should be treated as red flags. This is general information, not medical or legal advice.

The short answer: semaglutide and tirzepatide (the ingredients, not the brands)

The two GLP-1 molecules you will actually find compounded for weight loss are semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) and tirzepatide (the active ingredient in Mounjaro and Zepbound, technically a dual GIP/GLP-1 agonist). A compounding pharmacy starts from the raw drug substance and prepares a patient-specific formulation — most commonly an injectable drawn from a multi-dose vial, and in some cases an oral or sublingual preparation.

The critical framing that trips people up: you do not "compound a brand." Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are finished, FDA-approved drug products manufactured under the brand owner's New Drug Application. A pharmacy cannot lawfully replicate one of those finished products and call it the brand. What it can do — within the limits below — is compound the underlying active ingredient (semaglutide or tirzepatide) into a preparation for a specific patient. So a seller advertising "compounded Ozempic" or "compounded Zepbound" is using the language loosely at best; the accurate description is compounded semaglutide or compounded tirzepatide.

Why the drug-shortage list is the whole story

Compounding of these GLP-1s exploded in 2023–2024 for one reason: both molecules were on the FDA drug-shortage list. Federal law gives compounders far more latitude to make a copy of a commercially available drug when that drug is in shortage — and it specifically opens the door for 503B outsourcing facilities to compound in large batches from bulk drug substance while a drug appears on the shortage list. That shortage window is what allowed near-mass-scale production of compounded semaglutide and tirzepatide.

That window has now closed. The FDA resolved tirzepatide off the shortage list in late 2024, and semaglutide was removed in early 2025. With each drug off the shortage list, the broad shortage-based justification for mass compounding ended, and FDA set enforcement-discretion deadlines after which it could act against facilities still producing these molecules outside the narrow remaining exceptions. For the detailed timeline — the October 2, 2024 tirzepatide order, the December 19, 2024 re-affirmation, the 503A and 503B enforcement deadlines, and the related Outsourcing Facilities Association v FDA litigation — see our compounded tirzepatide FDA status tracker.

What remains legal after a drug leaves the shortage list is narrower and rests on a different legal footing. A 503A state-licensed pharmacy can still compound semaglutide or tirzepatide for an individually-identified patient when the prescriber documents a genuine clinical need that the FDA-approved product cannot meet — for example a documented allergy to an excipient in the commercial product, or a strength or formulation that is not commercially available. The legal basis is now clinical-need-based, not shortage-based. Cost savings, convenience, and prescriber preference do not qualify as a clinical need, and routine "essentially a copy of the commercial drug" compounding is restricted.

503A vs 503B — why some providers stopped and others continue

Two different compounding regimes explain why some telehealth platforms quietly stopped shipping compounded GLP-1s while others claim they can continue:

• Section 503A pharmacies are traditional state-licensed compounding pharmacies. They compound for an individually-identified patient against a valid prescription. After a drug leaves the shortage list, they may compound a product that is essentially a copy of a commercially available drug only when the prescriber documents a clinical difference for that specific patient. This is the pathway under which legitimate compounded semaglutide and tirzepatide still exist in 2026.
• Section 503B outsourcing facilities register with FDA, follow current good manufacturing practice, and can compound large batches without patient-specific prescriptions — but only from bulk drug substances on the FDA 503B bulks list or for drugs on the shortage list. With semaglutide and tirzepatide off the shortage list and not added to the bulks list for this purpose, large-batch 503B compounding of these molecules is generally no longer lawful.

Which GLP-1s can be compounded — the summary table

A drug-by-drug view of what can and cannot legitimately be compounded in 2026:

What is NOT — and should not be — compounded

Two offerings in particular should function as immediate red flags if a telehealth seller advertises them as compounded products:

• Compounded retatrutide. Retatrutide is an investigational triple-agonist still in clinical trials — it is not FDA-approved in any form. Because there is no approved finished product, there is no legitimate compounding pathway, and the FDA has specifically warned about compounded retatrutide being offered to consumers. Any platform selling "compounded retatrutide" is operating outside the legitimate compounding framework entirely.
• Compounded orforglipron ("Foundayo"). Orforglipron is a brand-only, on-patent, oral small-molecule GLP-1. It is an approved, patented finished product that has never been on the shortage list — none of the conditions that allow compounding apply. A "compounded orforglipron" offer is not a legitimate product. If you want orforglipron, the route is the brand via authorized channels; see our cheapest GLP-1 without insurance buyer's guide for the legitimate cash-pay tiers.

Separately, "research-chemical" or "for research use only" semaglutide and tirzepatide sold by chemistry-supply vendors are not compounded products at all — they are unregulated grey-market chemicals with no pharmacy involvement, no USP quality testing, and no patient-specific prescription. Compounding, by contrast, is performed by a licensed pharmacy against a valid prescription. Do not conflate the two.

What this means for patients in 2026

Legitimate compounded semaglutide and tirzepatide still exist — but the basis is now clinical need under a 503A patient-specific pathway, not the old shortage allowance. In practice, that means the price gap that drove the 2023–2024 compounded boom has narrowed sharply, because the manufacturers launched lower cash-pay channels (LillyDirect Self Pay, NovoCare) at the same time the broad compounding window closed. If you are evaluating a compounded GLP-1 today, the practical questions are: which molecule is it (it should be semaglutide or tirzepatide, described as the ingredient), what documented clinical need supports the 503A prescription, and is the dispensing pharmacy properly licensed and accredited.

If you decide compounded semaglutide is right for you after understanding the regulatory caveats, the providers below are the ones our editors have vetted on licensing, pharmacy partner, and dose transparency. Note this is an affiliate-supported shortlist for readers who have already chosen the compounded route — it is not a recommendation that compounded is preferable to the FDA-approved brands.

For the step-by-step legitimate-prescription workflow, see how to get semaglutide online. For the deep regulatory detail on the tirzepatide side — the declaratory orders, deadlines, and litigation — see compounded tirzepatide FDA status. For the brand cash-pay alternatives and how they now compare to compounded pricing, see cheapest GLP-1 without insurance. And for the molecule that started it all, see the Ozempic drug page and our ranking of the best semaglutide providers.

Bottom line

• The GLP-1s legitimately compounded for weight loss are semaglutide and tirzepatide — the active ingredients, compounded by a licensed pharmacy, not the brand-name finished products.
• You cannot compound a brand: Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are FDA-approved finished drugs. "Compounded Ozempic" is loose language for compounded semaglutide.
• The drug-shortage list is the hinge. Mass compounding was allowed while these drugs were in shortage; tirzepatide was resolved off the list in late 2024 and semaglutide in early 2025, ending the broad window.
• 503A patient-specific compounding survives narrowly — only with a documented clinical need the approved product cannot meet. Cost and convenience do not qualify.
• Retatrutide (investigational, FDA-warned) and orforglipron / Foundayo (brand-only, on-patent, never in shortage) are not compounding candidates — treat any "compounded" version as a red flag.
• Forms you will see: most commonly compounded injectable, with some oral or sublingual preparations.

Important disclaimer. This article is educational information only — not medical advice, not legal advice, and not a substitute for consultation with a licensed prescriber or a pharmacy compliance officer. Which GLP-1 molecules may be compounded, and under what conditions, is a YMYL topic governed by FDA enforcement posture, court rulings, and individual state boards of pharmacy — all of which change. Regulatory claims here were verified against FDA compounding and drug-shortage guidance and against our continuously-maintained compounded tirzepatide FDA status tracker; dates (tirzepatide resolved off the shortage list in late 2024, semaglutide in early 2025) are described at that level of precision deliberately. Weight Loss Rankings does not prescribe, dispense, or endorse any specific compounding pharmacy or grey-market product.